Longitudinal analysis of trastuzumab use in metastatic breast cancer

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 11513-11513
Author(s):  
A. Hammerman ◽  
S. Klang ◽  
N. Liebermann ◽  
N. Ben-Baruch
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Longitudinal Analysis ◽  
Real Life ◽  
Metastatic Breast ◽  
Molecular Characteristics ◽  
Duration Of Treatment ◽  
Trastuzumab Therapy ◽  
Sick Fund

11513 Background: Six years after including Trastuzumab in the Israeli ‘National Health Basket‘ (NHB) for metastatic breast cancer (MBC), we evaluated its ‘real-life‘ use in terms of duration of treatment (DOT) and survival after initiation of treatment. Methods: The computerized database of Clalit Health Services’ (CHS), the largest Israeli sick fund, was used to determine DOT and survival (at Dec. 31, 2005), in all CHS patients with MBC that started Trastuzumab therapy during years 2000–2003. Results: * At Dec. 31, 2005. ** However, most received AC as adjuvant. Conclusions: A longitudinal analysis of Trastuzumab use shows a difference of 40–100% between the median and mean DOT. This difference is attributed to a sizeable proportion (∼15%) of patients that are “long-term responders” and are treated for more than 24 months. In these patients, we can assume that the HER-2 amplification is an essential transforming event. We recommend investigating the molecular characteristics of long-term responders. [Table: see text] No significant financial relationships to disclose.

scholarly journals Long term continuous Trastuzumab use for HER2-positive advanced breast cancer

2020 ◽  
Vol 6 (5) ◽  
Author(s):  
Haider Y. Shukur
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Metastatic Breast ◽  
Loading Dose ◽  
Breast Cancer Patients ◽  
Her2 Positive ◽  
Trastuzumab Therapy ◽  
Locally Recurrent ◽  
Positive Breast Cancer

Objectives: Trastuzumab is the standard of care for locally advanced / metastatic her2-positive breast cancer. However, most of these patients will progress within 12 months of trastuzumab therapy. In contrast, there is a paucity of data available on the long-term treatment of patients with Trastuzumab. Our study was conducted to report efficacy and safety data for patients with locally recurrent / metastatic her2-positive breast cancer who received long-term therapy with Trastuzumab (≥5 years). Methods: This study was a prospective single-arm study of continuous Trastuzumab in patients who were histologically her2-positive and radiologically confirmed inoperable locally recurrent or metastatic breast cancer after complete one year of Trastuzumab plus chemotherapy (in hormone negative/hormone resistance) treatment then continuous Trastuzumab alone , or with hormone therapy (in sensitive hormone positive) without progression [complete or partial response or stable disease].  A total of 50 inoperable local recurrent and metastatic breast cancer  patients were treated with continuous intravenous Trastuzumab therapy administered according to the standard Trastuzumab every 3-weeks (8 mg/kg loading dose followed by 3-weekly 6  mg/kg maintenance doses starting 3 weeks after the loading dose) schedule, from January 2014 to January 2019 at the Najaf Cancer Clinic (NCC). Results: All 50 patients were evaluated with CR occur only in 20% (10/50) with an OAR of 50% (25/50). The cardiac status of these patients remained stable over time for the majority of patients with no marked changes in LVEF%. No treatment-related death was observed. The median OS and median PFS is 61 months and 20 months, respectively. Conclusion: In her2-positive recurrent and metastatic breast cancer patients, who initially respond to palliative treatment with trastuzumab, continuous trastuzumab can achieve a long-term tumor remission of several years and had significantly improved survival with tolerated and acceptable adverse events.

scholarly journals Cardiotoxicity Related to Long-Term Trastuzumab Therapy in Metastatic Breast Cancer: The Potential Role of Treatment Duration and Cardiac Risk Factors

2015 ◽  
Vol 21 (3) ◽  
pp. 318-321 ◽  
Author(s):  
Barbara Pistilli ◽  
Andrea Marcellusi ◽  
Luciano Latini ◽  
Roberto Accardi ◽  
Benedetta Ferretti ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Risk Factors ◽  
Metastatic Breast Cancer ◽  
Treatment Duration ◽  
Potential Role ◽  
Metastatic Breast ◽  
Cardiac Risk ◽  
Trastuzumab Therapy

Long-term responders with metastatic breast cancer (MBC) receiving eribulin: Real life experience.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. e13065-e13065
Author(s):  
Vera Gorbunova ◽  
Ludmila Manzyuk ◽  
Elena Kovalenko ◽  
Larisa Bolotina ◽  
Tatiana Semiglazova ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Life Experience ◽  
Real Life ◽  
Metastatic Breast

LONG-TERM RESPONDERS WITH METASTATIC BREAST CANCER (MBC) RECEIVING ERIBULIN: REAL LIFE EXPERIENCE

The Breast ◽  
2019 ◽  
Vol 48 ◽  
pp. S47
Author(s):  
Ludmila Zhukova ◽  
Vera Gorbunova ◽  
Ludmila Manzyuk ◽  
Elena Kovalenko ◽  
Irina Kalyadina ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Life Experience ◽  
Real Life ◽  
Metastatic Breast

scholarly journals Phenotypic discordance between primary and metastatic breast cancer in the large-scale real-life multicenter French ESME cohort

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Thomas Grinda ◽  
Natacha Joyon ◽  
Amélie Lusque ◽  
Sarah Lefèvre ◽  
Laurent Arnould ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Large Scale ◽  
Tumour Progression ◽  
Primary Tumour ◽  
Multivariable Analysis ◽  
Real Life ◽  
Metastatic Breast ◽  
Her2 Status ◽  
Risk Of Death

AbstractExpression of hormone receptor (HR) for estrogens (ER) and progesterone (PR) and HER2 remains the cornerstone to define the therapeutic strategy for breast cancer patients. We aimed to compare phenotypic profiles between matched primary and metastatic breast cancer (MBC) in the ESME database, a National real-life multicenter cohort of MBC patients. Patients with results available on both primary tumour and metastatic disease within 6 months of MBC diagnosis and before any tumour progression were eligible for the main analysis. Among the 16,703 patients included in the database, 1677 (10.0%) had available biopsy results at MBC diagnosis and on matched primary tumour. The change rate of either HR or HER2 was 27.0%. Global HR status changed (from positive = either ER or PR positive, to negative = both negative; and reverse) in 14.2% of the cases (expression loss in 72.5% and gain in 27.5%). HER2 status changed in 7.8% (amplification loss in 45.2%). The discordance rate appeared similar across different biopsy sites. Metastasis to bone, HER2+ and RH+/HER2- subtypes and previous adjuvant endocrine therapy, but not relapse interval were associated with an HR discordance in multivariable analysis. Loss of HR status was significantly associated with a risk of death (HR adjusted = 1.51, p = 0.002) while gain of HR and HER2 discordance was not. In conclusion, discordance of HR and HER2 expression between primary and metastatic breast cancer cannot be neglected. In addition, HR loss is associated with worse survival. Sampling metastatic sites is essential for treatment adjustment.

scholarly journals Post-surgical depressive symptoms and long-term survival in non-metastatic breast cancer patients at 11-year follow-up

2017 ◽  
Vol 44 ◽  
pp. 16-21 ◽  
Author(s):  
Michael H. Antoni ◽  
Jamie M. Jacobs ◽  
Laura C. Bouchard ◽  
Suzanne C. Lechner ◽  
Devika R. Jutagir ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Depressive Symptoms ◽  
Cancer Patients ◽  
Metastatic Breast ◽  
Breast Cancer Patients ◽  
Term Survival ◽  
Long Term Survival
Sign in / Sign up

Export Citation Format

Share Document